FDA Sends Warning Letter to Ozempic Maker Over Potential Unreported Side Effects The Food & Drug Administration (FDA) has sent a warning letter to the maker of popular diabetes and weight loss drugs Ozempic and Wegovy
Both reactive oxidant species from inhaled cigarette smoke and those endogenously formed by inflammatory cells constitute an increased intrapulmonary oxidant burden
GLP-1 and PYY3-36 as complementary gut hormones in the regulation of appetite and energy balance

Certain groups should exercise particular caution: Individuals with hypothyroidism , as L-carnitine may interfere with thyroid hormone action at the tissue level Those with seizure disorders , as the levocarnitine SmPC notes a possible association with increased seizure frequency, particularly in those with a prior history People with kidney disease , for whom unsupervised supplementation is not advised Pregnant or breastfeeding women , for whom safety data remains limited When to seek help: Call 999 immediately if you experience severe chest pain, sudden shortness of breath, or symptoms that could indicate a heart attack or stroke Contact NHS 111 for urgent concerns that are not immediately life-threatening Contact your GP promptly if you experience palpitations, significant gastrointestinal symptoms, new or worsening seizures, or any unexpected changes in health after starting supplementation If you suspect you have experienced a side effect from a supplement or medicine, you can report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk

Assess the pattern of glucose values and avoid repeated doses of insulin leading to hypoglycemia
If your symptoms are severe, your doctor may prescribe medication to help relax the muscles around your eyes